4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered? - Suppr

Suppr

超能文献

4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered?

作者信息

Giembycz Mark A

出版信息

Trends Pharmacol Sci. 2002 Dec;23(12):548. doi: 10.1016/s0165-6147(02)02089-8.

DOI:10.1016/s0165-6147(02)02089-8

PMID:12457768

Abstract

摘要

相似文献

4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered?

Trends Pharmacol Sci. 2002 Dec;23(12):548. doi: 10.1016/s0165-6147(02)02089-8.

Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors.

Br J Hosp Med (Lond). 2006 Jul;67(7):370-4. doi: 10.12968/hmed.2006.67.7.21622.

Phosphodiesterase inhibitors in airways disease.

Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. doi: 10.1016/j.ejphar.2005.12.059. Epub 2006 Feb 2.

Substituted furans as inhibitors of the PDE4 enzyme.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6. doi: 10.1016/s0960-894x(98)00742-2.

[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].

Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jan;27(1):57-9.

7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2137-40. doi: 10.1016/s0960-894x(00)00426-1.

PDE4 inhibitors: new xanthine analogues.

Bioorg Med Chem Lett. 1998 Oct 20;8(20):2925-30. doi: 10.1016/s0960-894x(98)00524-1.

8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.

Bioorg Med Chem Lett. 2002 Jun 17;12(12):1613-5. doi: 10.1016/s0960-894x(02)00223-8.

CC-10004 .

Curr Opin Investig Drugs. 2005 May;6(5):518-25.

Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).

Prog Drug Res. 1999;53:193-229. doi: 10.1007/978-3-0348-8735-9_5.

引用本文的文献

Inhibition of PDE4B ameliorates cognitive defects in the model of alcoholic dementia in 3xTg-AD mice via PDE4B/cAMP/PKA signaling.

Int J Neuropsychopharmacol. 2025 Mar 20;28(3). doi: 10.1093/ijnp/pyaf009.

PDE4B Missense Variant Increases Susceptibility to Post-traumatic Stress Disorder-Relevant Phenotypes in Mice.

J Neurosci. 2024 Oct 23;44(43):e0137242024. doi: 10.1523/JNEUROSCI.0137-24.2024.

Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease.

Neuropsychopharmacology. 2024 Sep;49(10):1559-1568. doi: 10.1038/s41386-024-01852-z. Epub 2024 Mar 23.

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).

BMJ Open Respir Res. 2023 Sep;10(1). doi: 10.1136/bmjresp-2022-001580.

Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System.

Biomolecules. 2023 Mar 5;13(3):476. doi: 10.3390/biom13030476.

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.

Eur Respir Rev. 2023 Feb 21;32(167). doi: 10.1183/16000617.0206-2022. Print 2023 Mar 31.

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.

Front Pharmacol. 2022 Apr 20;13:838449. doi: 10.3389/fphar.2022.838449. eCollection 2022.

Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice.

Biology (Basel). 2021 Dec 20;10(12):1355. doi: 10.3390/biology10121355.

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Drug Des Devel Ther. 2010 Jul 21;4:147-58. doi: 10.2147/dddt.s7667.

Evaluation of PDE4 inhibition for COPD.

Int J Chron Obstruct Pulmon Dis. 2006;1(4):373-9. doi: 10.2147/copd.2006.1.4.373.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验